Treatment of GCA still requires substantial exposure to glucocorticoids (GCs), which are associated with significant toxicity. This study compares the efficacy and safety of the GC-only standard of care (SOC) with a regimen combining intravenous methylprednisolone (IVMP) pulses, MTX and lower doses of prednisone, in newly diagnosed patients with GCA.

Neutrophil activation is heightened in inflammatory myopathies and associated with disease activity, yet its mechanisms remain unclear. This study explores the role of N-formyl methionine (fMET) in formyl peptide receptor 1 (FPR1)-mediated neutrophil activation in idiopathic inflammatory myopathies (IIMs), focusing on dermatomyositis (DM) and inclusion body myositis (IBM).

To evaluate the incidence and factors associated with SLE flares following HCQ discontinuation.

The long-term interaction between cardiovascular (CV) risk profiles and gout may influence the risk of cardiovascular events. However, the impact of gout and long-term changes in CV risk profile on CV events is unclear.

Evaluate the association of APS and SLE, focusing on LN, with risk of pre-eclampsia (PE) and PE with severity criteria (PESC).

To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR).

To manage OA-related pain, current guidelines recommend a combination of non-pharmacological and pharmacological treatments. The objective of this study was to assess a millimetre-wave-emitting medical device (MD) for neuromodulation of pain in patients with peripheral OA.

The worldwide epidemiology of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and peripheral spondyloarthritis, as well as of HLA-B27 and other MHC and non-MHC genes in these diseases, is reviewed herein. The frequency of axSpA is highest in circumpolar groups (such as Sami people and certain Indigenous American groups) and lowest in those of Japanese and African ancestry. The same pattern holds for PsA, although the overall prevalence of PsA seems much lower in East Asia, where it is less frequent than axSpA. The prevalence of PsA in people with psoriasis is increased where rheumatological assessment was carried out and seems to be increasing over time. HLA-B27 remains the most important genetic factor in axSpA susceptibility, although its frequency is lower in African American, South American and Middle Eastern populations than in others. The presence of HLA-B27 and other HLA alleles seems to be important in discerning clinical subsets of SpA and PsA, particularly those characterized by acute anterior uveitis or by axSpA with psoriasis, although these HLA-B27 and other MHC and non-MHC associations are derived from genome-wide association studies and other chip-based studies in large populations. These studies have been carried out mainly in populations of European and East Asian ancestry, and similar data from Latin America, sub-Saharan Africa and South Asia are lacking. This under-representation is an unmet need in applying genetic factors to understand the pathogenesis, diagnosis and classification of SpA and PsA.

Physical exercise is part of the recommended treatment for individuals with axial spondyloarthritis (axSpA). High-intensity interval training (HIIT) is an effective way to improve cardiovascular health without risk of increased disease activity. Nevertheless, there is a lack of knowledge regarding facilitating factors for digitally-based HIIT among individuals with axSpA.